Related Articles
Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer
Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression